Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Raed Alroughani

Showing results (171-180 of 223) with videos related to

Pageof 23
Sort By:
Therapeutic Advances in Neurological Disorders|November 11, 2024
The impact of COVID-19 infection on multiple sclerosis disease course across 12 countries: a propensity-score-matched cohort studyDavid Levitz, Yi Chao Foong, Paul Sanfilippo, et al.
Computer Methods and Programs in Biomedicine|February 18, 2025
Explainable time-to-progression predictions in multiple sclerosisRobbe D'hondt, Klest Dedja, Sofie Aerts, et al.
Brain : a Journal of Neurology|July 13, 2016
Defining secondary progressive multiple sclerosisJohannes Lorscheider, Katherine Buzzard, Vilija Jokubaitis, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|January 15, 2019
Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosisTomas Kalincik, Eva Kubala Havrdova, Dana Horakova, et al.
Annals of Neurology|October 7, 2014
Seasonal variation of relapse rate in multiple sclerosis is latitude dependentTim Spelman, Orla Gray, Maria Trojano, et al.
Brain : a Journal of Neurology|October 21, 2017
Towards personalized therapy for multiple sclerosis: prediction of individual treatment responseTomas Kalincik, Ali Manouchehrinia, Lukas Sobisek, et al.
JAMA Neurology|June 5, 2023
Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab CessationChao Zhu, Tomas Kalincik, Dana Horakova, et al.
Multiple Sclerosis and Related Disorders|August 2, 2022
Severity of COVID19 infection among patients with multiple sclerosis treated with interferon-βSteve Simpson-Yap, Ashkan Pirmani, Edward De Brouwer, et al.
JAMA Network Open|September 15, 2025
Pregnancy-Related Disease Outcomes in Women With Moderate to Severe Multiple Sclerosis DisabilityJessica Shipley, Heidi N Beadnall, Paul G Sanfilippo, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 30, 2014
Risk of relapse phenotype recurrence in multiple sclerosisTomas Kalincik, Katherine Buzzard, Vilija Jokubaitis, et al.
Pageof 23

Showing results (171-180 of 223) with videos related to

Sort By:
Pageof 23
Therapeutic Advances in Neurological Disorders|November 11, 2024
The impact of COVID-19 infection on multiple sclerosis disease course across 12 countries: a propensity-score-matched cohort studyDavid Levitz, Yi Chao Foong, Paul Sanfilippo, et al.
Computer Methods and Programs in Biomedicine|February 18, 2025
Explainable time-to-progression predictions in multiple sclerosisRobbe D'hondt, Klest Dedja, Sofie Aerts, et al.
Brain : a Journal of Neurology|July 13, 2016
Defining secondary progressive multiple sclerosisJohannes Lorscheider, Katherine Buzzard, Vilija Jokubaitis, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|January 15, 2019
Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosisTomas Kalincik, Eva Kubala Havrdova, Dana Horakova, et al.
Annals of Neurology|October 7, 2014
Seasonal variation of relapse rate in multiple sclerosis is latitude dependentTim Spelman, Orla Gray, Maria Trojano, et al.
Brain : a Journal of Neurology|October 21, 2017
Towards personalized therapy for multiple sclerosis: prediction of individual treatment responseTomas Kalincik, Ali Manouchehrinia, Lukas Sobisek, et al.
JAMA Neurology|June 5, 2023
Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab CessationChao Zhu, Tomas Kalincik, Dana Horakova, et al.
Multiple Sclerosis and Related Disorders|August 2, 2022
Severity of COVID19 infection among patients with multiple sclerosis treated with interferon-βSteve Simpson-Yap, Ashkan Pirmani, Edward De Brouwer, et al.
JAMA Network Open|September 15, 2025
Pregnancy-Related Disease Outcomes in Women With Moderate to Severe Multiple Sclerosis DisabilityJessica Shipley, Heidi N Beadnall, Paul G Sanfilippo, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 30, 2014
Risk of relapse phenotype recurrence in multiple sclerosisTomas Kalincik, Katherine Buzzard, Vilija Jokubaitis, et al.
Pageof 23